De novo variant detection with HiFi reads PacBie


Juniper A. Lake, William J. Rowell, Michael A. Eberle PacBio, 1305 O'Brien Drive, Menlo Park, CA 94025

Methods for detecting *de novo* mutations

Unencumbered by generations of selective pressure, *de novo* mutations (DNMs) are more likely to be deleterious than inherited variants and account for much of the variation driving rare disease. HiFi reads are useful for detecting DNMs because of their accuracy and length. To quantify the number of *de novo* single nucleotide variants (SNVs), small indels (<50 bp), and SVs, we analyzed six trios using HiFi sequence data derived from either cell lines (2 trios) or blood (4 trios).

Reference genomes GRCh38 and CHM13v2.0 detect distinct DNMs

On average, 55% of SNVs, 31% of indels, and 16% of SVs detected using GRCh38 were also detected with T2T-CHM13v2.0.



Characterizing DNMs by type and reference annotation

Most SNVs were non-coding and outside of repetitive regions. In contrast, most indels and structural variants overlapped at least 50% with tandem repeats, homopolymers, or segmental duplications. Insertions outnumbered deletions across variant sizes, with 1 bp insertions being the most common.






Figure 1. Pipeline overview. All members of each trio were sequenced with PacBio HiFi reads to $\sim 30 \times$ depth. Figure 2. Overlap of DNMs detected using GRCh38 vs CHM13v2.0. Choice of reference genome affects what DNMs are detected, especially for SVs.

More DNMs were detected with CHM13 than with GRCh38:

- 55% more SNVs
- 7% more indels
- 468% more SVs









Figure 4. Breakdown of DNMs by cohort, type, and reference annotation. INS=insertion, DEL=deletion, BND=breakend, INV=inversion, DUP=duplication, TR=tandem repeat, Segdup=segmental duplication. Variants were classified as TR/Homopolymer or Segdup if they overlapped at least 50% with reference genome regions annotated as such. Overlap with TR/Homopolymer regions was considered before overlap with segmental duplications.

- Trios 1–4 sequenced from blood
- Trios 5–6 sequenced from cell lines (HG002 and HG005, respectively)
- All samples sequenced to ~30× coverage and down-sampled for coverage comparisons
- Calls made with CHM13v2.0 were lifted over to GRCh38 for comparison

| | SNV | Indel | SV |
|------------------------------|-----------|-----------|----------|
| No missing | 5,635,203 | 1,303,998 | 30,142 |
| genotypes | 5,636,651 | 1,306,787 | 30,212 |
| Mendelian | 31,139 | 23,355 | 57 |
| inconsistency | 27,219 | 17,159 | 80 |
| Genotype | 799 | 497 | NA |
| quality ≥20 | 185 | 409 | |
| Child allele balance ≥0.2 | NA | NA | 20 56 |

Lower coverage produces many spurious DNMs

Reduced coverage (~10× vs. ~30×) in all samples or just parents produces many false positives (coverage dropout in parents) and false negatives (coverage dropout in child).



Conclusions

- In primary blood samples, we detected an average of 650 DNMs, most of which were insertions of 5 bp or less
- Most indels and structural variants are found in tandem repeats or homopolymers, where sequencing errors are more likely, and alignment is more difficult
- Genome reference has a substantial impact on the DNMs detected, especially for SVs
- Reduced coverage in parents (a common practice in rare disease

 Table 1. Average variants retained after each filter for
cell line trios (top) and blood sample trios (bottom). To capture only high-quality DNMs, we filtered variants that (1) had a missing genotype for any member of the trio, (2) showed mendelian consistency, (3) possessed a genotype quality score less than 20 in any sample (SNVs) or indels) or had an allele balance less than 0.2 in the child (SVs).

Figure 3. Intersection of DNMs detected in 30× trios, 10× trios, and trios with 10× parents and 30× child. Counts reflect all trios combined. Rows show DNMs detected in each set and columns show intersections between sets.

studies) increases false positive and false negative DNMs

Acknowledgements

The authors would like to thank Christine Lambert, Primo Baybayan, and Shreyasee Chakraborty for sequencing these samples.

Research use only. Not for use in diagnostic procedures. © 2022 Pacific Biosciences of California, Inc. ("PacBio"). All rights reserved. Information in this document is subject to change without notice. PacBio assumes no responsibility for any errors or omissions in this document. Certain notices, terms, conditions and/or use restrictions may pertain to your use of PacBio products. Refer to the applicable PacBio terms and conditions of sale and to the applicable license terms at pacb.com/license. Pacific Biosciences, the PacBio logo, PacBio, Circulomics, Omniome, SMRT, SMRTbell, Iso-Seq, Sequel, Nanobind, and SBB are trademarks of PacBio. All other trademarks are the sole property of their respective owners.